AMH: What does researchers
of ASRM have to say on AMH ??
News from American Society for Reproductive
Medicine (ASRM) 2016 Scientific Congress-- Low AMH levels predict poor outcome
in patients undergoing IVF-ET.
Patients aged >34 years with low AMH levels displayed poorer
IVF-ET outcome particularly, higher miscarriage rates that is not dependent on
age and ovarian response to COH.American Society for Reproductive Medicine
(ASRM) 2016 Scientific Congress is currently ongoing
(October 15 – 19) at Salt Lake City, Utah. Some
selected abstract and news from the conference are as follows:-
It is a
marker of ovarian function: What does it signfy?? “:--Anti-Mullerian Hormone (AMH) has long been
known to provide insight into ovarian function. AMH levels predict the treatment outcome in
controlled ovarian hyperstimulation The study findings support the hypothesis
that AMH levels are biomarker of oocyte and embryo reproductive health besides
predicting number of oocyte obtained by COH.
2) Manufactured where ?? :--It
is produced by small, growing follicles, thus providing us with quantitative
information on ovarian reserve. 2B) Why Amh hs become so popular parameter in
ART?? Researchers are more and more interested to evaluate its role in oocyte
competence and embryo health. After analyzing the data by binary logistic
regression, it was seen that clinical pregnancy and live birth rate were
directly proportional to levels of AMH, with miscarriage rate being highest in
the low AMH level group.
3) What are the negative points?? Ans;- no data is available on
its role in predicting miscarriages in
patients undergoing IVF-ET. But opinion varies because when the whole
population was included as one variable, regression analysis showed direct
association between patient’s AMH levels and rate of miscarriages independent
of age and number of oocyte retrieved.
Results of a
prospective study by Tarasconi B
et al at the ASRM 2016 conference shows the role played by levels of AMH and
subsequent miscarriage rate in patients undergoing IVF-ET. The paper is also
published in a special supplement of Journal Fertility and Sterility.
The study authors examined 2,365 infertile women
undergoing 2,688 IVF-ET cycles. All the women included in the study had serum
AMH tested as reference with ELISA. Women were classified into 3 age groups:
≤33 years (n=1,033), 34-36 years (n=690) and ≥37 years (n=965) and into 3
different AMH groups: Low AMH (0.04-1.60 ng/mL; n=540), Intermediate AMH
(1.61-5.59 ng/mL; n=1,608), and High AMH (5.60-35.00 ng/mL; n=540).
The results were statistically significant in
older women in the two age groups of 34-36 years and ≥37 years.
No comments:
Post a Comment